A Sibling Donor, a Family History, and a Test That Can't Wait for Its Own Turnaround Time
His sibling is a full HLA match, ready to donate. Two relatives on his father's side died of blood cancers. Whether that pattern means the donor himself might silently carry the same risk is a question worth answering before, not after, the transplant.
Marcus L. is the third person in his family to sit across from a hematologist, though the first two conversations happened a generation apart and neither one was framed, at the time, as connected to this one: his father died of myelodysplastic syndrome in his sixties, and a paternal aunt was diagnosed with a hematologic malignancy in her fifties. At 31, a software developer whose diagnosis ten weeks ago traces back to an abnormal complete blood count on his employer's routine annual wellness screening, Marcus is now the third data point in a pattern nobody had reason to name a pattern until his own AML made it one.
He achieved morphologic remission after induction, and a full HLA-matched sibling donor has already come forward, ready and willing to donate for the allogeneic transplant his adverse-risk cytogenetics make appropriate in first remission. What complicates an otherwise straightforward donor match is that family pattern itself: two relatives on the same side of the family with hematologic malignancy raises real suspicion for an underlying germline predisposition syndrome, most likely one of the recognized genes like DDX41 or RUNX1.
That suspicion matters specifically because of who the donor is. A sibling sharing the same family history could, in principle, silently carry the same germline mutation without any disease manifestation of their own — and transplanting stem cells carrying that mutation into an already leukemia-prone recipient has, in real documented cases, resulted in donor-derived leukemia years later — the pattern Berger et al. (2017) reported for a DDX41-mutated sibling donor, and the reason the NCCN and European Hematology Association guidance both direct that related donors be screened when a familial predisposition is suspected. Comprehensive germline testing takes weeks to turn around, a timeline that sits uncomfortably against a post-remission transplant that shouldn't be delayed indefinitely either. His sister, told plainly why the question matters, has said she wants to be tested regardless of what it means for today's donor plan, a detail that makes the timing question easier to solve than the emotional one underneath it.
A donor's own hidden risk, on a transplant timeline that can't wait
I don't want to delay urgent transplant planning waiting on germline testing results. Proceed with the sibling donor workup in parallel on the standard timeline, and if results come back positive before infusion, we pivot to an alternative donor then. Delaying a post-remission transplant carries a real relapse risk of its own.
I understand the urgency, but I want to name the stakes plainly: there are real, documented cases of a germline-mutation-positive relative donor unknowingly transmitting a predisposition that later produced donor-derived leukemia in the recipient — Berger's 2017 report of a DDX41 sibling donor is the one everybody cites, and DDX41 is exactly the gene his father's MDS in his sixties should make us think of first, since DDX41-related disease characteristically presents late. That outcome is severe and largely irreversible once transplant has already happened. Given two relatives on the same side of his family with hematologic malignancy, I'd want germline testing rushed, not run on a standard parallel timeline.
The urgency concern is real, and so is the safety concern — I don't think either of you is wrong about what matters.
But a comprehensive germline panel on the patient himself isn't the fastest way to answer the specific question that matters right now, which is whether HIS SISTER carries the mutation. A targeted, single-gene rapid-turnaround test on the sibling, informed by the specific family history pattern, can answer the donor-safety question faster than waiting for a broad panel would — while his own full germline workup still gets sent on the standard timeline for future family counseling. That gets you urgency and safety together instead of trading one for the other.
Agreed: pursue rapid, targeted testing of the sibling donor for the gene most suggested by the family history pattern, run in parallel with routine transplant workup rather than sequenced before or after it. His own broader germline panel is sent on a standard timeline for future family counseling purposes. If the sibling tests positive, the team will pivot to an alternative donor source without meaningfully delaying the transplant timeline, since the targeted test's faster turnaround leaves enough runway to do so.